All In Biotech

Drug Trial Radar · NCT06840483

Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

Phase 2 Study of Zelenectide Pevedotin in Participants With NECTIN4 Amplified Advanced Breast Cancer

Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

66

Planned (sponsor's estimate)

Start

Mar 3, 2025

Primary completion

Jun 30, 2028

Study completion Dec 30, 2028

Sponsor

Lead sponsor
BicycleTx LimitedIndustry
Sponsor type
Industry
First posted
Feb 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a global, multicenter, open-label study that aims to assess the efficacy and safety of zelenectide pevedotin in participants with NECTIN4-amplified recurrent, unresectable, or metastatic breast cancer who have received prior therapy (see inclusion criteria below). The study will comprise of 2 cohorts. Cohort A will include participants with hormone receptor positive/ human epidermal growth factor receptor 2 negative \[HR+/HER2-\] breast cancer, whereas Cohort B will include participants with triple-negative breast cancer (TNBC).

Conditions

  • Breast Cancer

Interventions

  • Zelenectide pevedotin (BT8009)Drug

    Participants will receive zelenectide pevedotin on Days 1, and 8 of every 21-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors per RECIST version 1.1 as assessed by the InvestigatorTime frame: Up to approximately 3 years

Locations

18 sites in 7 countries. Site status is shown where the registry gives one.

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (SKCCC)

    Baltimore, Maryland

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Siteman Cancer Center

    St Louis, Missouri

  • Memorial Sloan Kettering Cancer Center - Main Campus

    New York, New York

  • Duke Cancer Institute

    Durham, North Carolina

  • Compass Oncology - Rose Quarter Cancer Center

    Portland, Oregon

  • Texas Oncology San Antonio

    San Antonio, Texas

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

  • UZ Leuven

    Leuven, Belgium

  • Oncopole Claudius Regaud

    Toulouse, France

  • Clinica Oncologica-Azienda Ospedaliero Universitaria delle Marche

    Ancona, Italy

  • Istituto Europeo di Oncologia

    Milan, Italy

  • Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRCCS IRST

    Meldola, Forli/Cesena, Italy

  • Hospital Quironsalud Barcelona

    Barcelona, Spain

  • Hospital Beata Maria Ana

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • The Royal Marsden NHS Foundation Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.